Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days

Ocugen (OCGN) was in the spotlight on Friday after the biotech firm announced that its experimental gene therapy for an eye disorder received provisional approval and priority designation in the Bahamas, marking another step in its efforts to expand access to the treatment outside the U.S.The compa…